RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
May 3, 2024
RegMed Investors (RMi) Closing Bell: green on the sector screen, with a trickle starting to the downside
May 3, 2024
RegMed Investors’ (RMi) pre-open: No single indicator is a guide to sector share pricing conditions
May 2, 2024
RegMed Investors (RMi) Closing Bell: a sigh of relief as sector adds value after earnings releases
May 2, 2024
RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results
May 2, 2024
RegMed Investors’ (RMi) pre-open: Don't get excited as May evolves
May 1, 2024
RegMed Investors (RMi) Closing Bell: the path forward
May 1, 2024
RegMed Investors’ (RMi) pre-open: buckle up
April 30, 2024
RegMed Investors (RMi) Closing Bell: ending April on a sour note
April 30, 2024
RegMed Investors’ (RMi) pre-open: what will be, will be
April 29, 2024
RegMed Investors (RMi) Closing Bell: a month of up, downs; I thought were exercise
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors